A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Sims, MD
Seagen Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
54 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alberta / Cross Cancer Institute
Edmonton, Alberta, Canada
- London Health Sciences Centre - Victoria Hospital
London, Ontario, Canada
- Ciusss de L'Est de L'Lle de Montreal / Installation Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
- Jewish General Hospital
Montreal, Quebec, Canada
- Royal Victoria Hospital, Mcgill University Health Centre
Montreal, Quebec, Canada
- University of Alabama at Birmingham
Birmingham, Alabama, United States
- University of South Alabama - Mitchell Cancer Institute
Mobile, Alabama, United States
- Alaska Urological Institute
Anchorage, Alaska, United States
- Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
- Arizona Cancer Center / University of Arizona
Tucson, Arizona, United States
- Arizona Oncology Associates, Pc - Hope
Tucson, Arizona, United States
- Highlands Oncology Group
Springdale, Arkansas, United States
- Providence St Joseph Medical Center
Burbank, California, United States
- City of Hope National Medical Center
Duarte, California, United States
- Wilshire Oncology Medical Group Inc.
Pomona, California, United States
- Rocky Mountain Cancer Centers - Aurora
Aurora, Colorado, United States
- Florida Cancer Affiliates
Trinity, Florida, United States
- Iact Health
Columbus, Georgia, United States
- Georgia Cancer Specialists / Northside Hospital Cancer Institute
Sandy Springs, Georgia, United States
- Rush University Medical Center
Chicago, Illinois, United States
- Illinois Cancer Specialists / Advocate Lutheran General Hospital
Niles, Illinois, United States
- American Oncology Networks Llc
Bethesda, Maryland, United States
- Karmanos Cancer Institute / Wayne State University
Detroit, Michigan, United States
- Minnesota Oncology Hematology P.A.
Minneapolis, Minnesota, United States
- Nebraska Cancer Specialists
Omaha, Nebraska, United States
- Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
- Morristown Medical Center/ Carol G. Simon Cancer Center
Morristown, New Jersey, United States
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- New York Oncology Hematology, P.C.
Albany, New York, United States
- Columbia University Medical Center
New York, New York, United States
- James P. Wilmot Cancer Center / University of Rochester Medical Center
Rochester, New York, United States
- Oncology Hematology Care
Cincinnati, Ohio, United States
- James Cancer Hospital / Ohio State University
Columbus, Ohio, United States
- Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, United States
- Northwest Cancer Specialists, P.C.
Tigard, Oregon, United States
- Prisma Health
Greenville, South Carolina, United States
- Arlington Cancer Center
Arlington, Texas, United States
- Texas Oncology - Bedford
Bedford, Texas, United States
- Texas Oncology - Presbyterian Cancer Center Dallas
Dallas, Texas, United States
- Texas Oncology - Denton South
Denton, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2012
- Primary completion
- 7 Apr 2023
- Completion
- 12 Sept 2023
- Last update posted
- 11 Jun 2024
- Registered enrollment
- 131
- Registry id
- NCT01716806
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.